biostudies-literatureUnknown43(4)Blanchard-Rohner GData on COVID-19 vaccine acceptability among parents of children with multisystem inflammatory syndrome (MIS-C) are limited. In this cohort of children with MIS-C, enrolled in the Swissped RECOVERY trial (NCT04826588), comparing intravenous immunoglobulins or methylprednisolone, who, in accordance with Swiss guidelines, were recommended for SARS-CoV-2 vaccination, 65% (73/112) of parents reported being vaccinated against SARS-CoV-2 before the MIS-C, while 70% were vaccinated after the MIS-C episode of their child. None of the children were vaccinated before the occurrence of the MIS-C, and only 9% (5/56) received the COVID-19 vaccine after the MIS-C. The predominant barriers to COVID-19 vaccination were concerns over potential side effects and insufficient support from their doctors. This The Pediatric infectious disease journal361-364https://www.ebi.ac.uk/biostudies/studies/S-EPMC10919269biostudies-literatureCOVID-19 Vaccine Acceptance Among Parents of Children With Multisystem Inflammatory Syndrome in Children.PMC10919269Iglowstein IWoerner APerez MHMartin ALSeiler MVanoni Fvon Kalckreuth CPavlovic MSchwendener Scholl KRogdo BWelzel TTruck JGysi SJanz IWechselberger KMettauer NSeveri Conti AVaezipour NMazzara CKoehler HWachinger TSwissped RECOVERY Trial GroupBeck IAgyeman PDonner BDuppenthaler ARohr MAmiet VWagner NZimmermann PWutz DCudre-Cung HPBieri APallivathukal SDonas AMeyer ATrachsel DFaust SNWhittaker EPolito AAebi CGrazioli SAtkinson ARiedel TKottanattu LZutter AHofer MBirkenmaier ALongchamp DHammer JLutolf Erni MKaiser DBielicki JAGermann SKohns MZohrer KHeininger USchobi NWeber KBressieux-Degueldre SPeter Kuen HReppucci DFerry TOppenheim RHrup KBailey DGNLorenz PBuettcher MFlade MNatterer JMeyer Sauteur PBordessoule AGlockler MSanchez CBlanchard-Rohner GL'Huillier ABrotschi BSchlapbach LJStritt JSchlaeppi CPachlopnik Schmid JPrader SAndre MCfalseCOVID-19 Vaccine Acceptance Among Parents of Children With Multisystem Inflammatory Syndrome in Children.Data on COVID-19 vaccine acceptability among parents of children with multisystem inflammatory syndrome (MIS-C) are limited. In this cohort of children with MIS-C, enrolled in the Swissped RECOVERY trial (NCT04826588), comparing intravenous immunoglobulins or methylprednisolone, who, in accordance with Swiss guidelines, were recommended for SARS-CoV-2 vaccination, 65% (73/112) of parents reported being vaccinated against SARS-CoV-2 before the MIS-C, while 70% were vaccinated after the MIS-C episode of their child. None of the children were vaccinated before the occurrence of the MIS-C, and only 9% (5/56) received the COVID-19 vaccine after the MIS-C. The predominant barriers to COVID-19 vaccination were concerns over potential side effects and insufficient support from their doctors. This 2024-01-01T00:00:00Z2024 Apr2026-06-12T10:07:20.159Z2025-04-04T12:34:34.494ZS-EPMC109192693824166110.1097/INF.0000000000004206